BioStacks

Supplement

Streptococcus salivarius K12

Evidence

Moderate
Evidence: 3 of 5 (Moderate)

What the evidence says

An oral probiotic (distinct from the dairy starter S. salivarius subsp. thermophilus). The BLIS K12 and M18 strains produce bacteriocins (salivaricins) and have RCTs for reduced streptococcal/viral pharyngitis, otitis media and oral biofilm/halitosis.

Moderate: multiple oral-health RCTs for K12/M18 strains.

Top Streptococcus salivarius K12 supplements

About Streptococcus salivarius K12

An oral probiotic (distinct from the dairy starter S. salivarius subsp. thermophilus). The BLIS K12 and M18 strains produce bacteriocins (salivaricins) and have RCTs for reduced streptococcal/viral pharyngitis, otitis media and oral biofilm/halitosis. Strain- and site-specific (oral cavity), not a gut probiotic.

What Streptococcus salivarius K12 supports

  • Moderate evidence for throat/ear infection reduction and oral health
  • Produces bacteriocins that antagonize oral pathogens

How much Streptococcus salivarius K12 to take

The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.

Effective

15

billion_cfu

K12/M18 oral RCTs use ~1-5 billion CFU/day (lozenge). Presence-only when in blends; nominal range.

Clinical evidence

Moderate clinical evidence. Moderate: multiple oral-health RCTs for K12/M18 strains.

NIH Fact Sheet